Alkem Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


60,719	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
985	985	1,206	604	591
529	529	449	402	390
1,624	1,624	1,063	1,214	1,397
61,887	—	—	—	—
638	638	−144	610	806
₹5,176.63	—	—	—	—

15,972	15,972	13,496	11,928	10,832
10.2%	10.2%	7.9%	10.2%	12.9%
0.03×	—	—	—	—

4.10×	—	—	—	—
20.41×	—	—	—	—
23.46×	—	—	—	—
45.99×	—	—	—	—
15,081	14,712	12,965	12,668	11,599
3,032	3,005	2,512	2,245	1,609
2,638	2,623	2,155	1,946	1,299
—	1,963	1,913	1,948	1,683
1,346	1,346	1,237	1,689	1,450
—	1,324	1,227	1,679	1,429
—	617	676	259	233

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALKEM₹5,079.00

Alkem Laboratories Ltd.

· Pharma & Health

₹ CrorePeersMANKIND TORNTPHARM IPCALAB LUPIN FORTIS AUROPHARMA LAURUSLABS BIOCONMcap ₹60,719 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	60,719.4
- Cash, Equiv & ST Investments	591.0	604.1	1,206.4	985.2	985.2
+ Minority Interest	389.7	402.3	448.8	528.8	528.8
+ Total Debt	1,396.7	1,214.0	1,062.8	1,623.5	1,623.5
Enterprise Value	—	—	—	—	61,886.6
Net Debt (memo)	805.7	609.9	-143.6	638.3	638.3
EV per Share	—	—	—	—	5,176.63

Total Capital	10,831.7	11,928.4	13,496.4	15,972.4	15,972.4
Total Debt/Total Capital	12.89	10.18	7.87	10.16	10.16
Total Debt/EV	—	—	—	—	0.03

EV/Sales	—	—	—	—	4.10
EV/EBITDA	—	—	—	—	20.41
EV/EBIT	—	—	—	—	23.46
EV/Free Cash Flow	—	—	—	—	45.99
Reference Items — Trailing FY Values
Sales	11,599.3	12,667.6	12,964.5	14,712.3	15,081.3
EBITDA	1,609.5	2,245.5	2,512.2	3,005.2	3,032.2
EBIT	1,299.0	1,946.2	2,155.0	2,623.2	2,637.6
Operating Cash Flow	1,682.5	1,948.1	1,912.8	1,963.0	—
Free Cash Flow	1,449.6	1,688.8	1,237.2	1,345.8	1,345.8
FCFF (free cash flow to the firm)	1,428.9	1,679.2	1,227.3	1,323.5	—
Capital Expenditure	232.9	259.3	675.6	617.3	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.